-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mass infection due to B.
infection immunity
Recently, a research article was published in the top medical journal NEJM.
prevention
The researchers assessed the relative effectiveness of a fourth dose of the vaccine versus a third dose given at least 4 months earlier in people 60 years of age or older
The primary analysis included 182,122 pairs
diagnosis
CONCLUSIONS: A fourth dose of BNT162b2 vaccine was effective in reducing the short-term risk of Covid-19-related outcomes in individuals who had received a third dose of the vaccine at least 4 months earlier
A fourth dose of the BNT162b2 vaccine was effective in reducing the short-term risk of Covid-19-related outcomes in individuals who had received a third dose of the vaccine at least 4 months earlier